WGSNasdaqServices-Health ServicesFiscal year ends December 31
GeneDx Holdings Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$66.29+2.68 (+4.21%)
Close on Oct 19, 2026
- Market cap
- $1.97B
- P/E (TTM)
- –
- Dividend yield
- –
GeneDx Holdings Corp. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Gene Dx | $423.09M | $302.29M | $194.38M | $122.23M | – | – | – | 99.0% | +40.0% |
| Other | $4.45M | $3.16M | $8.19M | – | – | – | – | 1.0% | +41.0% |
| Other | – | – | $8.19M | $112.46M | – | – | – | – | – |
| Other | – | $3.16M | $8.19M | – | – | – | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Diagnostic test revenue: | $416.67M | $302.16M | $195.65M | $227.33M | $205.10M | $175.35M | $191.67M | 97.5% | +37.9% |
| Patients with third-party insurance | $345.24M | $234.70M | $134.49M | $173.62M | $169.58M | $138.15M | $169.54M | 80.7% | +47.1% |
| Institutional customers | $70.07M | $65.12M | $59.50M | $46.12M | $31.72M | $35.20M | $20.89M | 16.4% | +7.6% |
| Other revenue | $10.87M | $3.29M | $6.91M | $7.36M | $7.10M | $3.97M | $4.51M | 2.5% | +230.1% |
| Self-pay patients | $1.36M | $2.34M | $1.67M | $7.59M | $3.81M | $2.00M | $1.24M | 0.3% | -41.9% |
By region
From the segment and revenue-disaggregation notes of GeneDx's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.